Paul T Quinlan insider trades

Open-market stock purchases and sales by Paul T Quinlan, General Counsel at Oruka Therapeutics, Inc, from SEC Form 4 filings since Jan 12, 2012.

Recent trades

DateStockTradeValue
Sep 21, 2026ORKA Oruka Therapeutics, IncSold$268K
Sep 21, 2026ORKA Oruka Therapeutics, IncSold$358K
Sep 21, 2026ORKA Oruka Therapeutics, IncSold$56.8K
Sep 21, 2026ORKA Oruka Therapeutics, IncSold$254K
Sep 21, 2026ORKA Oruka Therapeutics, IncBought (not open market)—
Sep 15, 2026ORKA Oruka Therapeutics, IncSold$99.4K
Aug 14, 2026ORKA Oruka Therapeutics, IncSold$385K
Aug 14, 2026ORKA Oruka Therapeutics, IncSold$1.1M
Aug 14, 2026ORKA Oruka Therapeutics, IncSold$1.6M
Aug 14, 2026ORKA Oruka Therapeutics, IncSold$1.1M
Aug 14, 2026ORKA Oruka Therapeutics, IncSold$1M
Aug 14, 2026ORKA Oruka Therapeutics, IncSold$428K
Aug 14, 2026ORKA Oruka Therapeutics, IncBought (not open market)—
Aug 14, 2026ORKA Oruka Therapeutics, IncBought (not open market)—
Jun 15, 2026ORKA Oruka Therapeutics, IncSold$51.1K
Mar 16, 2026ORKA Oruka Therapeutics, IncSold$30.3K
Jan 23, 2026ORKA Oruka Therapeutics, IncBought (not open market)—
Jan 23, 2026ORKA Oruka Therapeutics, IncBought (not open market)—

Companies traded

  • ORKA Oruka Therapeutics, Inc: 13 sales, last Sep 21, 2026
  • CBAY CymaBay Therapeutics, Inc: 10 sales, last Mar 22, 2024
  • TVIA TerraVia Holdings, Inc: 4 sales, last Mar 9, 2017
  • SZYM Solazyme Inc: 38 sales, last Mar 10, 2016

Get free alerts when Paul T Quinlan files a new trade →